ICON Partners With PHT for Handheld Electronic Patient Reported Outcomes Solutions

DUBLIN, IRELAND , a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has signed a technology partnership agreement with PHT, a leading provider of handheld electronic devices for use in clinical trials.

ICON will be able to provide PHT's LogPad� electronic patient diary solution and its mobile site-based data capture product, the SitePad? Tablet, to its clients. PHT clients will have access to ICON's Lifecycle Science group's significant experience in both the design and implementation of Patient Reported Outcomes (PRO) research and ICON's Interactive Technologies electronic Patient Reported Outcomes (ePRO) utilising ICOPhone? which is comprised of IVR (Interactive Voice Response) and IWR (Interactive Web Response) technology. In addition, clients will also be able to integrate data from ICON's IVR/IWR system with PHT's handheld solutions in real time in order to create a more efficient flow of information through one system.

"ICON has partnered with PHT in order to seamlessly offer clients a handheld electronic diary or mobile-site based tablet solution," commented Kris Gustafson, Senior Vice President Interactive Technologies and Lifecycle Sciences Group at ICON Clinical Research. "As more trials are collecting PRO data for primary or secondary endpoints, clients are requesting an integrated solution to manage all aspects of a clinical trial including ePRO on a handheld device."

"We are delighted to partner with ICON, as our clients can benefit from ICON's significant experience in both the design and implementation of PRO research," said Phil Lee, PHT's President and CEO. "Strategic partnerships are a key element of PHT's growth strategy, and our partnership with ICON has delivered immediate benefits to the clients of both companies."

ICON and PHT have already secured three new trials through the partnership. In addition to collaborating on new business opportunities, ICON's and PHT's global business development and marketing teams are working together to address customers' complete PRO requirements.

About ICON

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development -- from compound selection to Phase I-IV clinical studies. ICON teams have successfully conducted over 1,900 development projects and over 2,300 consultancy engagements across all major therapeutic areas. ICON currently has over 6150 employees, operating from 69 locations in 36 countries. Further information is available at www.iconplc.com.

About PHT Corporation

PHT is the market-leading provider of electronic patient reported outcome (ePRO) solutions used in more than 350 clinical trials by 90 biopharmaceutical clients. The proven LogPad� System and revolutionary SitePad? Tablet deliver the voice of the patient, in 80 languages, from homes and sites in 60 countries around the world. By capturing high-quality and time stamped assessments with minimal respondent burden, transmitted over reliable analog and wireless global technologies, sponsors are able to run smaller and more conclusive clinical research programs. Real-time study management through PHT StudyWorks? features eClinical data integration, standard and custom data summaries for compliance and enrolment, SafetyPRO? email alerts, and the industry's premier study archive. Patient experiences captured firsthand by PHT's ePRO Product Suite have been used successfully in at least 11 NDA submissions and seven approvals to date. For more information, review interactive product demonstrations at the award-winning www.phtcorp.com.

For more information, please contact: For ICON Clinical Research: Susan Dempsey Global Marketing Manager Email Contact +353 1 291 2057 For PHT: Kris Sarajian Email Contact +1 617-973-1706

ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024